Milestone Pharmaceuticals
MIST
50 hedge funds and large institutions have $85.5M invested in Milestone Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 15 increasing their positions, 15 reducing their positions, and 12 closing their positions.
77% more call options, than puts
Call options by funds: $840K | Put options by funds: $474K
0% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 15
4.71% less ownership
Funds ownership: 69.92% → 65.22% (-4.7%)
9% less funds holding
Funds holding: 55 → 50 (-5)
11% less capital invested
Capital invested by funds: $96.2M → $85.5M (-$10.6M)
42% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$1.46M |
| 2 |
BlackRock
New York
|
+$1.27M |
| 3 |
AFA
Alta Fundamental Advisers
New York
|
+$1.22M |
| 4 |
Barclays
London,
United Kingdom
|
+$751K |
| 5 |
BC
BIT Capital
Berlin,
Germany
|
+$500K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
B
Braidwell
Stamford,
Connecticut
|
-$4.61M |
| 2 |
RI
RTW Investments
New York
|
-$3.87M |
| 3 |
Morgan Stanley
New York
|
-$1.8M |
| 4 |
PVI
Pura Vida Investments
New York
|
-$1.47M |
| 5 |
Millennium Management
New York
|
-$972K |
MIST Hedge Fund Activity: Q1 2023 in Review
50 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Milestone Pharmaceuticals (MIST) for Q1 2023, worth a combined $85.5M — down 11% from $96.2M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of MIST and 7 opened new positions — a net loss of 5 holders — while 15 trimmed existing stakes and 15 added.
The largest buyer was Point72 Asset Management, adding an estimated $1.46M. The largest seller was Braidwell, exiting entirely with an estimated $4.61M sold.
- 50 institutional investors held Milestone Pharmaceuticals (MIST) as of Q1 2023, down from 55 in Q4 2022.
- Funds reported $85.5M of Milestone Pharmaceuticals stock for Q1 2023, down 11% quarter-over-quarter.
- 7 funds opened new Milestone Pharmaceuticals positions in Q1 2023 and 12 closed out, a net change of -5 holders.
- The largest Milestone Pharmaceuticals buyer in Q1 2023 was Point72 Asset Management, an estimated $1.46M added.
- The largest Milestone Pharmaceuticals seller in Q1 2023 was Braidwell, an estimated $4.61M sold.
Based on aggregated 13F filings for Q1 2023.